Skip to main content
. 2024 Mar 27;15:97. doi: 10.1186/s13244-024-01623-w

Table 1.

Baseline characteristics of included patients diagnosed with HCC

Total (n = 265) Training cohort (n = 184) Validation cohort (n = 81) p value
Age (years) 62.80 ± 10.38 63.12 ± 10.18 62.09 ± 10.87 0.675
Sex (n, %)
 Male 210 (79.25) 145 (78.80) 66 (81.48) 0.618
 Female 55 (20.75) 39 (21.20) 15 (81.48)
Etiology (n, %)
 HBV/HCV 199 (75.09) 138 (75.00) 61 (75.31) 0.957
 None 66 (24.91) 46 (25.00) 20 (24.69)
AFP (n, %)
 ≥ 20 ng/mL 107 (40.38) 78 (42.39) 29 (35.80) 0.314
 < 20 ng/mL 158 (59.62) 106 (57.61) 52 (64.20)
ALT (U/L) 26.80 (18.50–39.60) 26.85 (18.40–39.65) 26.20 (18.60–35.30) 0.715
AST (U/L) 31.75 (25.99–43.15) 31.80 (25.60–42.90) 31.70 (26.40–45.40) 0.814
TB (μmol/L) 13.60 (10.90–19.20) 13.25 (10.88–19.20) 15.00 (11.10–19.90) 0.253
PT (s) 12.20 (11.60–13.00) 12.30 (11.60–13.00) 12.10 (11.60–12.80) 0.438
Albumin (g/L) 40.31 (37.40–43.50) 40.20 (36.80–43.15) 40.80 (37.90–44.90) 0.134
Child–Pugh grade (n, %)
 A 237 (89.43) 166 (90.22) 71 (87.65) 0.532
 B 28 (10.57) 18 (9.78) 10 (12.35)
PS (n, %)
 0 262 (98.87) 182 (98.91) 80 (98.77) 0.917
 1 3 (1.13) 2 (1.09) 1 (1.23)
HCC number (n, %)
 Solitary 253 (95.47) 176 (95.65) 77 (95.06) 0.831
 Two 12 (4.53) 8 (4.35) 4 (4.94)
BCLC stage (n, %)
 0 ~ A 235 (88.68) 166 (90.22) 69 (85.19) 0.234
 B ~ C 30 (11.32) 18 (9.78) 12 (14.81)
HCC differentiation (n, %)
 Well/moderately 52 (11.4)/151 (53.85) 43 (22.27)/102 (54.40) 9 (15.51)/49 (58.33) 0.680
 Poorly 74 (26.71) 48 (24.87) 26 (30.95)

HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha-fetoprotein, ALT alanine aminotransferase, AST aspartate aminotransferase, TB total bilirubin, PT prothrombin time, PS performance status, BCLC Barcelona Clinical Liver Cancer. HCC differentiation rate was calculated based on HCC number (n = 277)